Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14428)	12/2/2004 11:12:43 AM
From: Sam Citron	Respond to of 52153

Thanks, Peter. <eom>

To: Biomaven who wrote (14428)	12/2/2004 12:56:15 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Doesn't Macugen have to be approved first? <vbg> Even with PFE as a partner, I still don't see this as a slam dunk. After Vioxx, the leaderless FDA is likely to be a bit more gunshy especially when there are safety concerns and questionable efficacy relative to existing approved treatments. IMO, Ian ENZN is about at breakeven, and will likely move into profitability with royalties from Macugen.

To: Biomaven who wrote (14428)	12/14/2004 8:45:12 PM
From: tom pope	Respond to of 52153

Abelcet their anti-fungal is facing increased competition. You were right Peter. Briefing reports ENZN is halted. Enzon Pharmaceuticals Inc. (ENZN.O: Quote, Profile, Research) on Tuesday lowered its company sales forecast for fiscal 2005, citing weaker-than-expected demand for its Abelcet injectable antifungal medicine. The Bridgewater, New Jersey-based company said it expects North American sales of the drug to be between $55 million and $60 million in the fiscal year ending June 30, 2005. That compares with the company's earlier forecast of $69 million to $73 million.